ArticleOncoTargets and therapy2018
Negative correlation of cytoplasm TIMP3 with miR-222 indicates a good prognosis for NSCLC.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Biological Characteristics of Stromal Cells Differ Between Primary Lung Adenocarcinoma, Peritumoral Lung, and Distal Lung Tissues.Stem cells international · 2026Article
- The therapeutic potential of RNA m(6)A in lung cancer.Cell communication and signaling : CCS · 2024Review
- Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer.Biomedicines · 2023Review
- mCancer gene therapy · 2022Article
- Down-regulated expression ofAnnals of translational medicine · 2022Article
- Identification of novel transcription factor-microRNA-mRNA co-regulatory networks in pulmonary large-cell neuroendocrine carcinoma.Annals of translational medicine · 2021Article
- Associations ofInternational journal of molecular sciences · 2020Article
- Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.Theranostics · 2020Article
- Knockdown of miR-222 inhibits inflammation and the apoptosis of LPS-stimulated human intervertebral disc nucleus pulposus cells.International journal of molecular medicine · 2019Article
- Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis.Cancers · 2019Review
- Article
- Effects of VEGFR1Journal of cancer research and clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to observe the expression of microRNA-222 (miR-222) and matrix metalloproteinase inhibitor 3 (TIMP3) in non-small cell lung cancer (NSCLC) and discuss their significance.
methodsA total of 230 patients with NSCLC were enrolled in the observation group during the operation. Ninety-eight normal adjacent tissues were used as the control group. Two groups of miR-222 and TIMP3 were detected by in situ hybridization and immunohistochemistry. The distribution of miR-222 and TIMP3 in A549/H358/PC9 cells was observed by immunofluorescence. Chi-squared and Spearman correlation tests were used to analyze the relationship among miR-222, TIMP3 expression, and clinicopathological parameters of NSCLC. Kaplan-Meier and Cox proportional hazards regression were used to analyze the prognostic impact of miR-222 and TIMP3.
resultsImmunohistochemistry showed that the expression of miR-222 in lung cancer tissue was significantly higher, but TIMP3 was lower than that in normal lung tissue (
conclusionTIMP3 expression in lung cancer is relatively low and has a negative correlation with lung cancer staging and prognosis, suggesting that it may play a defensive function in the development of lung cancer, while miR-222 has the opposite effect, and the expression of both proteins is negatively correlated, suggesting that in lung cancer progresses, both proteins may play some role together.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.